Nexturn Bio Inc. acquired a 50% stake in RosVivo Therapeutics, Inc.
PR89705
SEOUL, South Korea, May 30, 2021 /PRNewswire=KYODO JBN/ --
- Nexturn Bio Inc. acquired a 50% stake in RosVivo Therapeutics, Inc.
Nexturn Bio Inc., a subsidiary of Nexturn Bioscience Co., Ltd., announced on
May 26th that it had acquired a 50% stake in RosVivo Therapeutics Inc.
("Rosvivo"), an American new drug developer, for about 5.5 million U.S. dollars.
As a result, Nexturn Bio Inc. strengthens its capabilities as a bio-company by
cooperating in the development of new medication pipelines utilizing miRNA
technology to target diabetes, obesity, non-alcoholic fatty liver disease
(NAFLD), gastrointestinal (GI) dysmotility, and COVID-19.
Nexturn Bio Inc. decided to invest in RosVivo and its miRNA technology through
due diligence and valuation by industry-leading law firms, patent corporations,
strategy consulting firms, and domestic and overseas accounting firms. Nexturn
also consulted with multiple key opinion leaders in endocrinology and
gastroenterology and received positive feedback regarding the efficacy of the
new drug.
According to a market report from Global Market Insights, the global diabetes
drugs market was valued at about $65.5 billion (USD) in 2019. The top global
pharmaceutical companies such as AstraZeneca, Novo Nordisk, Eli Lilly, and
Sanofi have increased revenue by participating in the early stage development
of diabetes drugs. This corresponds to an April 2020 study by GoodRx, an
American telemedicine platform providing comparisons of prescription drug
prices, which described diabetes as an expensive chronic disease. A diabetic
patient spends approximately an average of $222 and $476 per month for
non-insulin and insulin drugs.
However, regardless of this high out-of-pocket expense, conventional diabetes
drugs today still have not solved the problem of frequent administration and
various side effects. Many diabetic treatments depend on alleviating symptoms,
which is temporarily effective. Thus, developing a drug to treat the
fundamental cause of diabetes is urgently needed.
RosVivo's new miRNA drug RSVI-301 significantly reduces injection frequency,
showed a prolonged effect, and alleviated side effects such as GI dysmotility
in animal studies. It is expected that RSVI-301 will become a first-in-class
diabetic drug.
"We consider this project not only as a successful investment, but also as a
great opportunity to develop an innovative diabetic treatment in collaboration
with RosVivo," said an official at Nexturn Bio Inc. "We will do our best to
demonstrate the market potential of RosVivo's miRNA-based pipelines as an
innovative anti-diabetic medication."
In addition to the anti-diabetic pipeline, RSVI-301, RosVivo is planning to
collaborate with established universities and healthcare institutions to start
clinical trials for RosVivo's other treatment pipeline named RSVI-305/306,
which will target COVID-19.
SOURCE NEXTURN Bio Inc.
Image Attachments Links:
Link: http://asianetnews.net/view-attachment?attach-id=392009
Caption: Global Antidiabetics Pharma Companies and drugs
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。